Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.
Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Marell P, et al. Among authors: mcwilliams r. Oncologist. 2024 Dec 14:oyae342. doi: 10.1093/oncolo/oyae342. Online ahead of print. Oncologist. 2024. PMID: 39674576 Free article.
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Chakrabarti S, et al. Among authors: mcwilliams rr. Oncologist. 2020 May;25(5):380-e763. doi: 10.1634/theoncologist.2019-0874. Epub 2019 Dec 11. Oncologist. 2020. PMID: 31826977 Free PMC article. Clinical Trial.
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience.
Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. Gile JJ, et al. Among authors: mcwilliams rr. JCO Precis Oncol. 2021 Jul 28;5:PO.21.00064. doi: 10.1200/PO.21.00064. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778691 Free PMC article.
Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma.
Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Gile JJ, et al. Among authors: mcwilliams rr. Target Oncol. 2022 Sep;17(5):529-538. doi: 10.1007/s11523-022-00914-w. Epub 2022 Sep 2. Target Oncol. 2022. PMID: 36056231
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Tella SH, et al. Among authors: mcwilliams rr. Oncologist. 2023 Oct 3;28(10):917-e966. doi: 10.1093/oncolo/oyad144. Oncologist. 2023. PMID: 37339254 Free PMC article. Clinical Trial.
Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
Huffman BM, Jin Z, Yadav S, Patel S, Nagorney DM, Truty MJ, McWilliams RR, Halfdanarson TR, Mahipal A. Huffman BM, et al. Among authors: mcwilliams rr. Clin Colorectal Cancer. 2019 Sep;18(3):218-225. doi: 10.1016/j.clcc.2019.05.002. Epub 2019 May 15. Clin Colorectal Cancer. 2019. PMID: 31178274
426 results